Top Medical News
Tonsillectomy may lower risk of psoriasis
22 hours ago
Patients who received tonsillectomy have a lower risk of psoriasis, reports a study, following adjustment for baseline characteristics, comorbidities, and medical confounders relative to a comparison group.
Patients with vitiligo at risk of hearing loss
23 hours ago
A significant association exists between vitiligo and sensorineural hearing loss (SNHL), according to a recent study, which recommends audiologic assessment for early recognition and management of hearing loss in patients with vitiligo.
Hidradenitis suppurativa bidirectionally linked to atopic dermatitis
23 hours ago
A recent study has found a two-way association between hidradenitis suppurativa (HS) and atopic dermatitis (AD), warning dermatologists to be aware of this relationship.
Psoriasis ups risk of colorectal cancer
Patients with psoriasis appear to be at greater risk for developing colorectal cancer, suggests a recent study, noting how gastroenterology consultation and colonoscopic examination are indicated for such individuals presenting with bowel symptoms.
Lanadelumab demonstrates sustained efficacy for HAE
Audrey Abella, 19 Nov 2021
The monoclonal antibody lanadelumab demonstrated long-term efficacy for patients with hereditary angioedema (HAE) who had received prophylactic lanadelumab for ≥12 months, according to findings from the post hoc analysis of the phase III HELP OLE* study presented at ACAAI 2021.
COVID toe: What does it tell you?
Elvira Manzano, 17 Nov 2021
New research suggests that COVID toe – a form of COVID-19–associated pernio or chilblains – may be a side effect of the immune system's response to fighting off the virus.
Gel from tree bark: First effective treatment for epidermolysis bullosa
12 Nov 2021
In patients with recessive dystrophic epidermolysis bullosa (RDEB), larger wound size is predictive of worsening skin disease severity and quality of life (QOL), reports a recent study. Worsening skin disease severity is significantly associated with key clinical manifestations.
Special Reports
Product Highlight - RELIZEMA
16 Jun 2021
Furfuryl Palmitate
Expert consensus: Patient profile should guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
Antihistamine therapy for allergic rhinitis and urticaria: An Asia-Pacific perspective
01 Nov 2018
The prevalence of allergic diseases in the Asia-Pacific region is expected to rise over the next 20 years, driven by rapid economic development and urbanization. Allergic diseases have high socioeconomic impact by impairing productivity and quality of life, and the impact may be greater in Asia-Pacific than in Europe due to the presence and predominance of perennial allergens.
Improving Medical Practice through Advancement in Clinical Treatment: IMPACT Aesthetics & Suturing Workshop 2018
Dr. Steven Ang, Dr. Leo Kah Woon, 11 Jul 2018
DCH Auriga recently held their first Aesthetics and Suturing Workshop under the IMPACT continuing medical education series – a scientific platform that aims to cascade the latest updates on disease management and share best clinical practices among healthcare professionals in Singapore. Two experts on aesthetics and aesthetic surgery shared their insights on suturing techniques and current approaches for scar prevention and management.
Cochrane review confirms Atopiclair efficacy in eczema
22 Dec 2017
Eczema (atopic dermatitis) is a chronic inflammatory skin disease that can present in many different forms. However, it is principally characterized by dry skin, intense itching, and the presence of inflammatory skin lesions. [J Eur Acad Dermatol Venereol 2016;30:604-618; N Engl J Med 2008;358:1483-1494; Lancet 2016;387:1109-1122]
Product Highlight – Canesten HC
12 Apr 2017
CANESTEN HC – Clotrimazole 1% w/w and hydrocortisone 1% w/w cream – Bayer
Acne scarring: A shift from treatment to prevention
09 Dec 2016
All patients with acne are potentially at risk of scarring. Professor Goh Chee Leok addresses this issue by focussing on preventing the development of scars in his talk at the 41st Annual Meeting of the Dermatological Society of Malaysia held in Kuching, Sarawak.
Conference Reports
Ruxolitinib cream improves repigmentation in patients with vitiligo
Elaine Soliven, 09 Nov 2021
The application of ruxolitinib cream led to significant improvements in facial and total body repigmentation among adolescents and adults with vitiligo, according to two phase III studies presented at EADV 2021.
Ritlecitinib prevents hair loss in patchy baldness
Pearl Toh, 22 Oct 2021
The oral selective Janus kinase 3 (JAK3) inhibitor ritlecitinib effectively prevents hair loss in people with alopecia areata (AA) compared with placebo, according to the ALLEGRO study presented at EADV 2021.
Elaine Soliven, 22 Oct 2021
Maintenance treatment with bimekizumab achieves complete scalp, palmoplantar, or nail clearance in patients with moderate-to-severe plaque psoriasis, according to two phase III trials presented at EADV 2021.
Roflumilast cream eases itch severity in chronic plaque psoriasis
Roshini Claire Anthony, 19 Oct 2021

In patients with chronic plaque psoriasis, once-daily treatment with roflumilast improved severity and burden of itch compared with vehicle cream, according to results of the phase III DERMIS-1 and DERMIS-2 trials presented at EADV 2021.

Tapinarof a new kid on the block for plaque psoriasis
Elvira Manzano, 18 Oct 2021
Treatment with the nonsteroidal topical cream tapinarof 1% for up to 52 weeks helps control plaque psoriasis in the phase III PSOARING 3 trial.
Abrocitinib trumps dupilumab for itch relief in AD
Pearl Toh, 16 Oct 2021
The oral selective JAK*1 inhibitor abrocitinib is superior to dupilumab for relieving itch and achieving skin clearance in people with moderate-to-severe atopic dermatitis (AD), according to results from a head-to-head comparison in the JADE DARE trial presented at EADV 2021.
Baricitinib: A potential treatment for alopecia areata?
Roshini Claire Anthony, 14 Oct 2021

Baricitinib, an oral, selective Janus kinase (JAK)1/JAK2 inhibitor, may help improve hair growth in patients with severe alopecia areata, according to results from the phase III BRAVE-AA1 and BRAVE-AA2 trials.

Product Highlights
CME Modules